Piperacillin sodium
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03911 |
| CAS | 59703-84-3 |
| Molecular Weight | 539.54 |
| Molecular Formula | C23H27N5O7SNa |
| Purity | >98% |
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-03911 | 25 g | $299 | In stock | |
| BBF-03911 | 50 g | $524 | In stock |
Online Inquiry
Add to cartCapabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections.
- Specification
- Properties
- Reference Reading
- Price Product List
| Synonyms | CL227193; CL 227193; CL-227193 |
| Storage | Store at 2-8°C |
| IUPAC Name | sodium;(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| Canonical SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+] |
| InChI | InChI=1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1 |
| InChI Key | WCMIIGXFCMNQDS-IDYPWDAWSA-M |
| Source | Pseudomonas sp. |
| Appearance | White to Off-white Powder |
| Application | Anti-Bacterial Agents |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Boiling Point | 707.1°C at 760 mmHg |
| Melting Point | 183-185°C (dec.) |
1.Epidemiology of Acute Kidney Injury Among Patients Receiving Concomitant Vancomycin and Piperacillin/tazobactam: Opportunities for Antimicrobial Stewardship.
Karino S1, Kaye KS1, Navalkele B1, Nishan B2, Salim M2, Solanki S2, Pervaiz A2, Tashtoush N2, Shaikh H2, Koppula S2, Martin ET3, Mynatt RP4, Murray KP5, Rybak MJ6, Pogue JM7. Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.03011-15. [Epub ahead of print]
BACKGROUND: Despite their common use as empiric combination therapy for the better part of a decade there has been a recent association between combination therapy with vancomycin and piperacillin/tazobactam and high rates of acute kidney injury (AKI). Reasons for this increased association are unclear and this analysis was designed to investigate the association.
2.The Distribution and Resistance of Pathogens Among Solid Organ Transplant Recipients with Pseudomonas aeruginosa Infections.
Wan Q1, Luo A2, Zhong Z3, Ye Q4. Med Sci Monit. 2016 Apr 5;22:1124-1130.
BACKGROUND Pseudomonas aeruginosa infection remains a life-threatening complication after solid organ transplantation (SOT). We aimed to investigate the distribution and drug susceptibility of pathogens, and clinical characteristics of SOT recipients with Pseudomonas aeruginosa infections. MATERIAL AND METHODS A total of 55 SOT recipients who developed 61 episodes of Pseudomonas aeruginosa infections between January 1, 2003 and July 31, 2015 were retrospectively analyzed. The distribution and the drug susceptibility of Pseudomonas aeruginosa were reviewed. RESULTS The most common site from which 61 Pseudomonas aeruginosa rods were isolated were the lungs (57.4%, n=37), followed by the blood (27.9%, n=17). There were 35, 18, and 9 recipients accompanied with a serum creatinine level of >1.5 mg/dL, lymphocyte count of <300/mm3, and a serum albumin level of <30 g/L, respectively. Seven patients each presented with white blood cell count of >15 000/mm3 and platelet count of <50 000/mm3.
3.Piperacillin concentration in relation to therapeutic range in critically ill patients - a prospective observational study.
Zander J1, Döbbeler G2, Nagel D1, Maier B1, Scharf C2, Huseyn-Zada M1, Jung J3, Frey L2, Vogeser M1, Zoller M4. Crit Care. 2016 Apr 4;20(1):79. doi: 10.1186/s13054-016-1255-z.
BACKGROUND: Piperacillin levels after standard dosing have been shown frequently to be subtherapeutic, especially when renal clearance was augmented. Here, we aimed to determine if piperacillin was in its therapeutic range in a typically heterogeneous intensive care unit patient group, and also to describe target attainment dependent on daily dosage, creatinine clearance, and renal replacement therapy (RRT).
4.[Role of bacteriobilia in postoperative complications].
Armiñanzas C, Tigera T, Ferrer D, Calvo J, Herrera LA, Pajarón M, Gómez-Fleitas M, Fariñas MC1. Rev Esp Quimioter. 2016 Apr 8. pii: farinas08apr2016. [Epub ahead of print]
OBJECTIVE: At present there is a controversy regarding the impact of positive bile cultures on morbidity and mortality rates, and on the incidence of readmissions in patients with biliar disease. The aim of this study was to evaluate the role of bacteriobilia in postoperatory infections, mortality or readmissions in these patients.
| BBF-04655 | Exatecan Mesylate | Inquiry |
| BBF-00586 | Brefeldin A | Inquiry |
| BBF-03891 | Cefsulodin sodium | Inquiry |
| BBF-03963 | Pristinamycin | Inquiry |
| BBF-03868 | Honokiol | Inquiry |
| BBF-05818 | Docosahexaenoic acid | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
